Patents by Inventor Xichen Lin

Xichen Lin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240083886
    Abstract: Relates to GLP-1 agonists of Formula (I): including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.
    Type: Application
    Filed: October 13, 2021
    Publication date: March 14, 2024
    Inventors: Qinghua MENG, Weiqiang XING, Xichen LIN, Andrew JENNINGS
  • Patent number: 11926643
    Abstract: This disclosure relates to GLP-1 agonists of Formula (I): including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.
    Type: Grant
    Filed: June 29, 2022
    Date of Patent: March 12, 2024
    Assignee: Gasherbrum Bio, Inc.
    Inventors: Qinghua Meng, Xichen Lin, Haizhen Zhang, Weiqiang Xing, Hui Lei, Andrew Jennings
  • Patent number: 11926626
    Abstract: This disclosure relates to GLP-1 agonists of Formula (I), including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.
    Type: Grant
    Filed: September 21, 2022
    Date of Patent: March 12, 2024
    Assignee: Gasherbrum Bio, Inc.
    Inventors: Qinghua Meng, Weiqiang Xing, Haizhen Zhang, Xichen Lin, Hui Lei, Andrew Jennings
  • Patent number: 11897851
    Abstract: This disclosure relates to GLP-1 agonists of Formula I: including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.
    Type: Grant
    Filed: February 6, 2023
    Date of Patent: February 13, 2024
    Assignee: Gasherbrum Bio, Inc.
    Inventors: Qinghua Meng, Hui Lei, Haizhen Zhang, Xichen Lin, Andrew Jennings
  • Publication number: 20240018102
    Abstract: This disclosure relates to LPA antagonists of Formula (I): including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.
    Type: Application
    Filed: October 21, 2021
    Publication date: January 18, 2024
    Applicant: Lhotse Bio, Inc
    Inventors: Haizhen Zhang, Michael Hanson, Andrew Jennings, Hui Lei, Xichen Lin, Qiong Zhang, Alexandre Cote, Anatoly M. Ruvinsky
  • Publication number: 20230391760
    Abstract: This disclosure relates to GLP-1 agonists of Formula (I): including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.
    Type: Application
    Filed: October 13, 2021
    Publication date: December 7, 2023
    Inventors: Qinghua MENG, Weiqiang XING, Xichen LIN, Andrew JENNINGS
  • Publication number: 20230331732
    Abstract: This disclosure relates to GLP-1 agonists of Formula (I), including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.
    Type: Application
    Filed: September 8, 2021
    Publication date: October 19, 2023
    Inventors: Qinghua MENG, Weiqiang XING, Haizhen ZHANG, Xichen LIN, Hui LEI, Andrew JENNINGS
  • Publication number: 20230322771
    Abstract: This disclosure relates to GLP-1 agonists of Formula (I), including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.
    Type: Application
    Filed: September 6, 2021
    Publication date: October 12, 2023
    Inventors: Qinghua MENG, Weiqiang XING, Haizhen ZHANG, Xichen LIN, Hui LEI, Andrew JENNINGS
  • Publication number: 20230295154
    Abstract: This disclosure relates to GLP-1 agonists of Formula (I): including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.
    Type: Application
    Filed: April 28, 2021
    Publication date: September 21, 2023
    Inventors: Qinghua MENG, Andrew JENNINGS, Hui LEI, Xichen LIN
  • Publication number: 20230192633
    Abstract: This disclosure relates to GLP-1 agonists of Formula I: including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.
    Type: Application
    Filed: February 6, 2023
    Publication date: June 22, 2023
    Inventors: Qinghua Meng, Hui Lei, Haizhen Zhang, Xichen Lin, Andrew Jennings
  • Publication number: 20230174565
    Abstract: This disclosure relates to GLP-1 agonists of Formula (I): including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.
    Type: Application
    Filed: June 29, 2022
    Publication date: June 8, 2023
    Inventors: Qinghua MENG, Xichen LIN, Haizhen ZHANG, Weiqiang XING, Hui LEI, Andrew JENNINGS
  • Publication number: 20230165846
    Abstract: Provided are GLP-1 agonists of Formula (I) or (II), including pharmaceutically acceptable salts and solvates thereof, pharmaceutical compositions, and methods of using the same.
    Type: Application
    Filed: February 9, 2021
    Publication date: June 1, 2023
    Inventors: Qinghua MENG, Xichen LIN, Andrew JENNINGS
  • Publication number: 20230107793
    Abstract: This disclosure relates to GLP-1 agonists of Formula (I), including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.
    Type: Application
    Filed: September 21, 2022
    Publication date: April 6, 2023
    Inventors: Qinghua MENG, Weiqiang XING, Haizhen ZHANG, Xichen LIN, Hui LEI, Andrew JENNINGS
  • Publication number: 20230071840
    Abstract: This disclosure relates to GLP-1 agonists of Formula (I), including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.
    Type: Application
    Filed: September 22, 2022
    Publication date: March 9, 2023
    Inventors: Qinghua MENG, Weiqiang XING, Haizhen ZHANG, Xichen LIN, Hui LEI, Andrew JENNINGS
  • Patent number: 11492365
    Abstract: This disclosure relates to GLP-1 agonists of Formula (I): including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.
    Type: Grant
    Filed: January 7, 2022
    Date of Patent: November 8, 2022
    Assignee: GASHERBRUM BIO, INC.
    Inventors: Qinghua Meng, Xichen Lin, Haizhen Zhang, Hui Lei, Andrew Jennings
  • Publication number: 20220213130
    Abstract: This disclosure relates to GLP-1 agonists of Formula (I): including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.
    Type: Application
    Filed: January 7, 2022
    Publication date: July 7, 2022
    Inventors: Qinghua Meng, Xichen Lin, Haizhen Zhang, Weiqiang Xing, Hui Lei, Andrew Jennings
  • Patent number: 10336719
    Abstract: The invention relates to 1-(3-sulfonylphenyl)-3-(cyclopent-2-en-1-yl)urea derivatives, and their use in treating or preventing diseases and conditions mediated by the CXCR2 receptor. In addition, the invention relates to compositions containing the derivatives and processes for their preparation.
    Type: Grant
    Filed: September 13, 2018
    Date of Patent: July 2, 2019
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Weichun Chen, Ebere F Igboko, Xichen Lin, Hongfu Lu, Feng Ren, Paul Bryan Wren, Zhongmiao Xu, Ting Yang, Lindong Zhu
  • Publication number: 20190010135
    Abstract: The invention relates to 1-(3-sulfonylphenyl)-3-(cyclopent-2-en-1-yl)urea derivatives, and their use in treating or preventing diseases and conditions mediated by the CXCR2 receptor. In addition, the invention relates to compositions containing the derivatives and processes for their preparation.
    Type: Application
    Filed: September 13, 2018
    Publication date: January 10, 2019
    Inventors: Weichun Chen, Ebere F. Igboko, Xichen Lin, Hongfu Lu, Feng Ren, Paul Bryan Wren, Zhongmiao Xu, Ting Yang, Lindong Zhu
  • Patent number: 10106515
    Abstract: The invention relates to 1-(3-sulfonylphenyl)-3-(cyclopent-2-en-1-yl)urea derivatives, and their use in treating or preventing diseases and conditions mediated by the CXCR2 receptor In addition, the invention relates to compositions containing the derivatives and processes for their preparation.
    Type: Grant
    Filed: May 27, 2015
    Date of Patent: October 23, 2018
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Weichun Chen, Ebere F Igboko, Xichen Lin, Hongfu Lu, Feng Ren, Paul Bryan Wren, Zhongmiao Xu, Ting Yang, Lingdong Zhu
  • Patent number: 10005731
    Abstract: The present invention relates to novel retinoid-related orphan receptor gamma (ROR?) modulators and their use in the treatment of diseases mediated by ROR?.
    Type: Grant
    Filed: December 5, 2013
    Date of Patent: June 26, 2018
    Assignee: Glaxo Group Limited
    Inventors: Fangbin Han, Hui Lei, Xichen Lin, Qinghua Meng, Yonghui Wang